Homocysteine and folic acid: Implications for pregnancy

Seminars in Vascular Medicine

Volumn 5, Issue 2, 2005, Pages 190-200

  Daly, Sean ^a   Cotter, Amanda ^b   Molloy, Ann E ^c   Scott, John ^c  

^a Pathology Research Laboratory   (Ireland)

^b UNIVERSITY OF MIAMI   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Folic acid; Homocysteine; Pregnancy

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE;

CLEFT LIP PALATE; CLEFT PALATE; CONGENITAL HEART DISEASE; DYSOSTOSIS; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LIMB DEFECT; METHYLATION; NEURAL TUBE DEFECT; OMPHALOCELE; PREECLAMPSIA; PREGNANCY; REVIEW; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; URINARY TRACT MALFORMATION; VITAMIN SUPPLEMENTATION;

CANADA; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HEMATINICS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INTERNATIONAL COOPERATION; NATIONAL HEALTH PROGRAMS; NEURAL TUBE DEFECTS; PRE-ECLAMPSIA; PREGNANCY; UNITED STATES;

EID: 21744454670     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872404     Document Type: Review

References (101)

1. Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997;65:1790-1795
2. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation inmethylene-tetrahydrofolate reductase. Nat Genet 1995;10:111-113
3. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9
4. Molloy AM, Daly S, Mills JL, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997;349:1591-1593
5. Weir DG, Scott JM. Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications. Nutrition Research Reviews 1998;11:311-338
6. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057
7. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999;131:363-375
8. Ueland PM, Refsum H, Stabler SP, Malinow MR, Anderson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-1779
9. Cotter AM, Daly SF. Neural tube defects: is a decreasing prevalence associated with a decrease in severity? Eur J Obstet Gynecol Reprod Biol 2005;119:161-163
10. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N Engl J Med 1999;341:1509-1519
11. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137
12. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-1835
13. Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004;350:134-142
14. Forrest JD. Epidemiology of unintended pregnancy and contraceptive use. Am J Obstet Gynecol 1994;170:1485-1489
15. Higgins M, Daly SF. Poor compliance with folic acid supplementation recommendations among women in Dublin. Proceedings of the Irish Perinatal Society Spring Meeting; 2004
16. United States Food and Drug Administration. Food Standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996;61:8781-8797
17. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285:2981-2986
18. Persad VL, Van den Hof MC, Dube JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 2002;167:241-245
19. Committee on Medical Aspects of Food and Nutrition Policy (COMA) Report on Health and Social Subjects. 50: Folic acid and the prevention of disease. London: The Stationery Office; 2000
20. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-151
21. Essien FB, Wannberg LS. Methionine but not folic acid or Vitamin B-12 altered the frequency of neural tube defects in axd mutant mice. J Nutr 1993;123:27-34
22. Coelho CN, Weber JA, Klein NW, Daniels WG, Hoagland TA. Whole rat embryos require methionine for neural tube closure when cultured on cow serum. J Nutr 1989;119:1716-1725
23. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975;4:37-44
24. Hill L, Murphy M, McDowall M, Paul AH. Maternal drug histories and congenital malformations: limb reduction defects and oral clefts. J Epidemiol Community Health 1988;42:1-7
25. Haves C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996;143:1229-1234
26. Czeizel AE, Timar L, Sarkozi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. Pediatrics 1999;104:e66
27. Kallen B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 2003;40:624-628
28. Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 1995;346:393-396
29. Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y. Maternal multivitamin use and orofacial clefts in offspring. Teratology 2001;63:79-86
30. Loffredo LC, Souza JM, Freitas JA, Mossey PA. Oral clefts and vitamin supplementation. Cleft Palate Craniofac J 2001;38:76-83
31. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. Am J Epidemiol 1999;150:675-682
32. Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. Teratology 1996;53:345-351
33. Peer L, Gordon HW, Bernhard WG. Effects of vitamins on human teratology. Plast Reconstr Surg 1964;34:358-361
34. Tolarova M, Harris J. Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins. Teratology 1995;51:71-78
35. Ray JG, Meier C, Vermeulen MJ, Wyatt PR, Cole DE. Association between folic acid food fortification and congenital orofacial clefts. J Pediatr 2003;143:805-807
36. van Rooij IA, Swinkels DW, Blom HJ, Merkus HM, Steegers-Theunissen RP. Vitamin and homocysteine status of mothers and infants and the risk of nonsyndromic orofacial clefts. Am J Obstet Gynecol 2003;189:1155-1160
37. Shaw GM, Rozen R, Finnell RH, Todoroff K, Lammer EJ. Infant C677T mutation in MTHFR, maternal periconceptional vitamin use, and cleft lip. Am J Med Genet 1998;80:196-198
38. Shaw GM, Todoroff K, Finnell RH, Rozen R, Lammer EJ. Maternal vitamin use, infant C677T mutation in MTHFR, and isolated cleft palate risk. Am J Med Genet 1999;85:84-85
39. Mills JL, Kirke PN, Molloy AM, et al. Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. Am J Med Genet 1999;86:71-74
40. Jugessur A, Wilcox AJ, Lie RT, et al. Exploring the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 Norwegian case-parent triads. Am J Epidemiol 2003;157:1083-1091
41. Martinelli M, Scapoli L, Pezzetti F, et al. C677T variant form at the MTHFR gene and CL/P: a risk factor for mothers? Am J Med Genet 2001;98:357-360
42. Prescott NJ, Winter RM, Malcolm S. Maternal MTHFR genotype contributes to the risk of non-syndromic cleft lip and palate. J Med Genet 2002;39:368-369
43. Jugessur A, Lie RT, Wilcox AJ, et al. Cleft palate, transforming growth factor alpha gene variants, and maternal exposures: assessing gene-environment interactions in case-parent triads. Genet Epidemiol 2003;25:367-374
44. Little J, Cardy A, Munger RG. Tobacco smoking and oral clefts: a meta-analysis. Bull World Health Organ 2004;82:213-218
45. Shaw GM, Wasserman CR, O'Malley CD, Nelson V, Jackson RJ. Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology 1999;10:60-66
46. Marazita ML, Mooney MP. Current concepts in the embryology and genetics of cleft lip and cleft palate. Clin Plast Surg 2004;31:125-140
47. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S A 1996;93:15227-15232
48. Burgoon JM, Selhub J, Nadeau M, Sadler TW. Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model. Teratology 2002;65:219-227
49. Junker R, Kotthoff S, Vielhaber H, et al. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 2001;51:251-254
50. Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am Obstet Gynecol 2001;184:806-812
51. Shaw GM, Zhu H, Lammer EJ, Yang W, Finnell RH. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. Am J Epidemiol 2003;158:747-752
52. Storti S, Vittorini S, Lascone MR, et al. Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. Clin Chem Lab Med 2003;41:276-280
53. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C Semin Med Genet 2004;125 C(1):12-21
54. Czeizel AE, Dobo M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res A Clin Mol Teratol 2004;70:853-861
55. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol 2000;151:878-884
56. Botto LD, Khoury MJ, Mulinare J, Erickson JD. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 1996;98:911-917
57. Ness RB, Roberts JM. Heterogenous causes constituting the single syndrome of pre-eclampsia: A hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-1370
58. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr 2000;71:1344S-1352S
59. Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001;357:2002-2006
60. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long-term mortality of mothers and fathers after preeclampsia: population based cohort study. BMJ 2001;323:1213-1217
61. Funai EF, Friedlander Y, Paltiel O, et al. Long-term mortality after preeclampsia. Am J Obstet Gynecol 2002;187:354
62. Laivuori H, Kaaja R, Turpeinen U, Viinikka L, Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 1999;93:489-493
63. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-37
64. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-1048
65. Hubel CA, Snaedal S, Ness RB, et al. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG 2000;107:776-784
66. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-413
67. Weir DG, Scott JM. Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications. Nutrition Research Reviews 1998;11:311-338
68. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1997;20:307-315
69. Roberts JM, Redman CWG. Preeclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447-1451
70. Ashworth JR, Warren AY, Johnson IR, Baker PN. Plasma from preeclamptic women and functional change in myometrial resistance arteries. Br J Obstet Gynaecol 1998;105:459-461
71. Rajkovic A, Catalano PM, Malinow MR. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997;90:168-171
72. Rajkovic A, Mahomed K, Malinow MR, Sorensen TK, Woelk GB, Williams MA. Plasma homocysteine concentrations in eclamptic and preeclamptic African women post-partum. Obstet Gynecol 1999;94:355-360
73. Powers RW, Evans RW, Majors AK, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998;179:1605-1611
74. Murphy MM, Scott JM, McPartlin JM, Fernandez-Ballart JD. The pregnancy related decrease in fasting plasma homocysteine is not explained by folic supplementation, hemodilution or a decrease in albumin in a longitudinal study. Am J Clin Nutr 2002;76:614-619
75. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: A risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:781-785
76. Cotter AM, Molloy AM, Scott JM, DaIy SF. Elevated plasma homocysteine in early pregnancy: A risk factor for the development of nonsevere preeclampsia. Am J Obstet Gynecol 2003;189:391-394
77. Powers RW, Majors AK, Kerchner LJ, Conrad KP. Renal handling of homocysteine during normal pregnancy and preeclampsia. J Soc Gynecol Investig 2004;11:45-50
78. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997;77:1052-1054
79. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and preeclampsia. J Med Genet 1997;34:525-526
80. Powers RW, Minich LA, Lykins DL, Ness RB, Crombleholme WR, Roberts JM. Methylenetetrahydrofolate reductase polymorphism, folate and susceptibility to pre-eclampsia. J Soc Gynecol Investig 1999;6:74-79
81. Prasmusinto D, Skrablin S, Hofstaetter C, Fimmers R, van der Ven K. The methylenetetrahydrofolate reductase 677C → T polymorphism and preeclampsia in two populations. Obstet Gynecol 2002;99:1085-1092
82. Powers RW, Dunbar MS, Gallaher MJ, Roberts JM. The 677C → T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy. Obstet Gynecol 2003;101:762-766
83. Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland homocysteine study. Am J Clin Nutr 2000;71:962-968
84. Powers RW, Gandley RE, Lykins DL, Roberts JM. Moderate hyperhomocysteinemia decreases endothelial dependent vasorelaxation in pregnant but not non-pregnant mice. Hypertension 2004;44:327-333
85. Goddijn-Wessel TA, Wouters MG, van de Molen EF, et al. Hyperhomocysteinaemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996;66:23-29
86. Steegers-Theunissen RPM, Boers GHJ, Blom HJ, Trijbels FJM, Eskes TKAB. Hyperhomocysteinaemia and recurrent spontaneous abortion or abruptio placentae. Lancet 1992;339:1122-1123
87. de Vries JIP, Dekker GA, Huijgens PC, Jakobs C, Blomberg B, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997;104:1248-1254
88. Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 2000;71:1295S-1303S
89. de Weerd S, Steegers-Theunissen RP, de Boo TM, Thomas CM, Steegers EA. Maternal periconceptual biochemical and hematological parameters, vitamin profiles and pregnancy oucome. Eur J Clin Nutr 2003;57:1128-1134
90. Hibbard BM. The role of folic acid in pregnancy with particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Commonw 1964;71:529-542
91. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β synthase deficiency. Am J Hum Genet 1985;37:1-31
92. Wouters MG, Boers GH, Blom HJ, et al. Hyperhomocysteinaemia; a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-825
93. Nelen WL, Bulten J, Steegers EA, Blom HJ, Hanselaar AG, Eskes TK. Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss. Hum Reprod 2000;15:954-960
94. Nelen WL, Steegers EA, Eskes TK, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997;350:861
95. Hogge WA, Byrnes AL, Lanasa MC, Surti U. The clinical use of karyotyping spontaneous abortions. Am J Obstet Gynecol 2003;189:397-400
96. Roque H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004;91:290-295
97. Murphy MM, Scott JM, Arija V, Molloy AM, Fernandez-Ballart JD. Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight. Clin Chem 2004;50:1406-1412
98. Rolschau J, Kristoffersen K, Ulrich M, Grinsted P, Schaumberg E, Foged N. The influence of folic acid supplements on the outcome of pregnancies in the county of Funen in Denmark. Eur J Obstet Gynecol Reprod Biol 1999;87:105-110
99. Infante-Rivard C, Rivard GE, Gauthier R, Theoret Y. Unexpected relationship between plasma homocysteine and intrauterine growth restriction. Clin Chem 2003;49:1476-1482
100. van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG 2000;107:785-791
101. Wang J, Trudinger BJ, Duarte N, Wilcken DE, Wang XL. Elevated circulating homocysteine levels in placental vascular disease and associated preeclampsia. BJOG 2000;107:935-938